Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double masked, placebo controlled, parallel, multicenter study: To evaluate efficacy and safety of 3 % DE-089C ophthalmic solution in subject with Dry eye.

Next Previous
Trial Profile

A phase III, randomized, double masked, placebo controlled, parallel, multicenter study: To evaluate efficacy and safety of 3 % DE-089C ophthalmic solution in subject with Dry eye.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diquafosol (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Sponsors Santen Pharmaceutical

Most Recent Events

  • 18 Jun 2022 Primary endpoint (Change CFS score from Week 0 at Week 4) has been met according to the results published in the Advances in Therapy
  • 18 Jun 2022 Results assessing efficacy and safety of DE-089C in patients with dry eye compared to placebo published in the Advances in Therapy
  • 23 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top